[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"af---atrial-fibrillation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:af---atrial-fibrillation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,76,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100624556","wearable-device-assisted-remote-management-in-atrial-fibrillation-complicated-by-heart-failure-warm-hf-trial-100624556",false,"NCT07411170","Wearable Device-Assisted Remote Management in Atrial Fibrillation Complicated by Heart Failure: WARM-HF Trial","Wearable Device-assisted Remote Management for Patients With Atrial Fibrillation Complicated by Heart Failure: A Prospective, Open-label, Multi-center, Randomized Controlled Trial","WARM-HF","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Subjects diagnosed with acute decompensated heart failure (ADHF) :1)Heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40%;2)New York Heart Association (NYHA) functional class II-IV;3)NT-proBNP \\> 2500 pg\u002FmL or BNP \\> 600 pg\u002FmL\n3. Atrial fibrillation (AF) diagnosed during hospitalization (documented AF episode lasting \\> 30 seconds on electrocardiogram \\[ECG\\] within the past 12 months)\n\nExclusion Criteria:\n\n1. Intolerance to heart failure pharmacotherapy\n2. Severe anemia, uncorrected thyroid disease\n3. ST-segment elevation myocardial infarction (STEMI) within 3 months\n4. Known complex congenital\u002Fsecondary heart disease; infiltrative cardiomyopathy (e.g., cardiac amyloidosis, sarcoidosis, lymphoma, or endomyocardial fibrosis); myocarditis; constrictive pericarditis; cardiac tamponade; hypertrophic cardiomyopathy; stress cardiomyopathy (Takotsubo cardiomyopathy); or uncorrected primary valvular heart disease requiring surgical intervention.\n5. Previous or planned major cardiac surgery or mechanical circulatory support within 6 months, including coronary artery bypass grafting, cardiac valve repair or replacement, ventricular assist device or mechanical circulatory support device implantation, and heart transplantation.\n6. Current use of or planned implantation of a pacemaker.\n7. Contraindications to wearing a smartwatch (e.g., limb disability or known allergy to rubber\u002Fmetal materials)\n8. Inability to access the Internet or lack of proficiency in operating smart devices\n9. Pregnant or lactating women\n10. Organ transplantation within the past 12 months\n11. Expected survival time of less than 1 year for any reason\n12. Refusal to participate or inability to comply with follow-up requirements\n13. Deemed ineligible for participation in the study by the investigators","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","Patients with acute decompensated heart failure (HF) have a significantly high risk of death and HF re-hospitalization during the vulnerable phase post discharge. Therefore, early post-discharge management is crucial, and the cornerstone of HF treatment-particularly for HF with reduced ejection fraction (HFrEF)-is guideline-directed medical therapy (GDMT), a comprehensive pharmacotherapeutic strategy supported by robust clinical evidence. Timely titration of GDMT, especially within the first few weeks after discharge, has been shown to improve clinical outcomes, reduce readmissions, and enhance long-term prognosis. However, ensuring optimal follow-up and therapeutic adjustments remains a major challenge in real-world practice. Atrial fibrillation (AF) is a common comorbidity in patients with HF, especially in those with severe HF. The presence of AF significantly complicates the clinical course and worsens the prognosis of HF.\n\nAdvances in wearable technology have made continuous, non-invasive monitoring of vital signs, arrhythmia burden, and physical status increasingly feasible. Devices such as smartwatches and ECG belts can provide real-time physiological data, offering new opportunities for remote and proactive disease management. Despite the growing availability of such data, the complex interplay between AF and HF demands highly personalized management. Currently, there is a lack of high-quality clinical evidence on how to effectively integrate wearable device data into personalized strategies for this specific patient population.\n\nThis is an open-label, multi-center, endpoint-blinded, parallel-group randomized clinical trial supported by the American Heart Association. The primary objective is to determine whether wearable device-assisted digital consultations can optimize GDMT in patients with AF complicated by acute decompensated HF. The study plans to enroll 400 participants, who will be randomly assigned to either a wearable device-assisted intervention group or a conventional treatment control group. The primary endpoint is the change in HF GDMT score 3 months after randomization.\n\nApple Inc. provided funding, devices, and technical support for this study. Apple was not a sponsor of the trial and was not involved in its execution, data analysis, interpretation, or manuscript preparation.",[27,28],"HFrEF - Heart Failure With Reduced Ejection Fraction","AF - Atrial Fibrillation","NOT_YET_RECRUITING","2026-06-25",{"date":32,"type":33},"2026-06-29","ACTUAL",{"date":35,"type":21},"2026-08",{"date":37,"type":21},"2028-09",{"name":39,"class":40},"Beijing Anzhen Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100641603","abbreviated-antithrombotic-therapy-after-pci-in-patients-with-af-and-ami-100641603","NCT07583784","Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI","Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction","HERO-AF-AMI","Inclusion Criteria:\n\n1. Patients aged 19 years old\n2. Patients with AF and CHA2DS2-VA score ≥2.\n3. ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI)\n\n   * STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12\n   * NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12\n\n     1. Symptoms of ischemia.\n     2. New or presumed new significant ST-T wave changes\n     3. Development of pathological Q waves on electrocardiography.\n     4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.\n     5. Intracoronary thrombus detected on angiography.\n4. Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.\n\nExclusion Criteria:\n\n1. Patients contraindicated for use of DOACs or clopidogrel\n2. Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist\n3. Planned cardiac surgery within 1 year after randomization\n4. Patients with severe thrombocytopenia or coagulopathy\n5. Liver cirrhosis or severe hepatic dysfunction\n6. Advanced chronic kidney disease (creatinine clearance \\\u003C15 ml\u002Fmin\u002F1.73 m2) or on dialysis\n7. Prior history of intracranial hemorrhage\n8. Coexisting conditions related to high risk of life-threatening bleeding\n9. Pregnancy or breast feeding\n10. Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n11. Unwillingness or inability to comply with the procedures described in this protocol.","19 Years",{"count":51,"type":21},860,[24],"The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).",[55,56,57,28],"Myocardial Infarction (MI)","ST-Segment Elevation Myocardial Infarction(STEMI)","NSTEMI - Non-ST-Segment Elevation Myocardial Infarction",[59,60,61,62,63,64,65],"AF","Myocardial infarction","STEMI","NSTEMI","DOAC","NOAC","OAC alone","2026-06-15",{"date":68,"type":33},"2026-06-17",{"date":70,"type":21},"2026-07-01",{"date":72,"type":21},"2032-12-31",{"name":74,"class":40},"Chonnam National University Hospital",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100617257","safety-and-effectiveness-of-catheter-ablation-for-atrial-fibrillation-with-intracerebral-hemorrhage-safer-af-100617257","NCT07316270","SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracerebral Hemorrhage (SAFER-AF)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Between 14 Days and 12 Months After Spontaneous Intracerebral Hemorrhage\n3. Able to Access Intracerebral Hemorrhage Imaging Data\n4. ECG indicating the presence of atrial fibrillation\n5. CHA₂DS₂-VA Score ≥ 2\n6. Willing to undergo randomization and able to complete follow-up as required\n\nExclusion Criteria:\n\n1. Atrial fibrillation secondary to clearly reversible causes (e.g., hyperthyroidism, hypokalemia, etc.)\n2. Fully dependent (modified Rankin Scale \\[mRS\\] score \\> 4)\n3. Uncontrolled hypertension (systolic blood pressure \\> 160 mmHg)\n4. Presence of uncontrolled active bleeding\n5. Presence of active infection requiring antibiotic treatment\n6. End-stage renal failure or receiving dialysis treatment\n7. Presence of liver failure\n8. Untreated coronary artery disease with indication for revascularization\n9. Presence of intracardiac masses, thrombi, etc., as evaluated by transthoracic echocardiography or transesophageal echocardiography\n10. Expected life expectancy \\\u003C 1 year (e.g., advanced malignant tumors, etc.)\n11. Pregnant, lactating, or women planning to become pregnant\n12. Presence of psychological or psychiatric disorders that prevent understanding or cooperation with the study\n13. Other conditions deemed unsuitable for participation in the study by the investigators",{"count":83,"type":21},646,[24],"SAFER-AF is an investigator-initiated, multicenter, open-label, parallel-group trial comparing catheter ablation versus usual care in patients with atrial fibrillation and intracerebral hemorrhage.",[28,87],"ICH - Intracerebral Hemorrhage","2025-12-30",{"date":90,"type":33},"2026-01-05",{"date":92,"type":21},"2026-01",{"date":94,"type":21},"2030-01",{"name":39,"class":40},7,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":75},"100503926","pulmonary-vein-isolation-pvi-combined-with-renal-denervation-rdn-in-atrial-fibrillation-af-and-hypertension-htn-100503926","NCT05841615","Pulmonary Vein Isolation (PVI) Combined With Renal Denervation (RDN) in Atrial Fibrillation (AF) and Hypertension (HTN)","Evaluation of the Safety and Efficacy of Pulmonary Vein Isolation (PVI) Combined With Renal Denervation (RDN) in Patients With Atrial Fibrillation (AF) and Hypertension (HTN)","Inclusion Criteria:\n\n* 18\\\u003Cage\\\u003C75years\n* clinic blood pressure≥140\u002F90mmHg or 24-hour ambulatory blood pressure monitoring average blood pressure ≥135\u002F85mmHg\n* Ecg diagnosis of atrial fibrillation ;\n* who signed informed consent and were approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University.\n\nExclusion Criteria:\n\n* pregnant women or lactating patients;\n* Patients who were unsuitable for ablation before surgery （unilateral or bilateral renal artery shape and structure were found： renal artery stenosis exceeding 50%, renal aneurysm, previous renal artery interventional surgery, renal artery malformation, renal artery diameter \\\u003C 4mm or length of treatable segment \\\u003C 20mm）\n* Patients who only have one kidney or have a history of kidney transplantation\n* Patients with a history of renal arterial intervention or renal denervation\n* identified secondary hypertension or Pseudo hypertension except for renal parenchymal hypertension;\n* malignant tumors or end-stage diseases;\n* Severe peripheral vascular disease, abdominal aortic aneurysm\n* whose left atrium is larger than 55mm\n* obvious bleeding tendency and blood system diseases;\n* Severe peripheral vascular disease, abdominal aortic aneurysm;\n* A history of the acute coronary syndrome within two weeks;\n* acute or severe systemic infection;\n* drug or alcohol dependence or refusal to sign informed consent.\n* Other conditions that are not suitable for PVI and RDN","75 Years",{"count":106,"type":21},120,[24],"The close relationship between the increase of sympathetic tension, AF, and HTN cannot be ignored. In addition, the significant failure rate of PVI (20-50%) in the treatment of AF makes it very necessary to explore the effect of RDN on AF. Therefore, this study aims to compare the effects and safety of PVI alone and PVI combined with RDN with AF combined with HTN, which will open a new chapter for PVI combined with RDN in the treatment of AF.",[28,110],"HTN-Hypertension",[112,113,114,115],"Pulmonary Vein Isolation (PVI)","Renal Denervation (RDN)","Atrial Fibrillation (AF)","Hypertension (HTN)","RECRUITING","2024-03-11",{"date":119,"type":33},"2024-03-13",{"date":121,"type":33},"2023-09-01",{"date":123,"type":21},"2028-04-30",{"name":125,"class":40},"The First Affiliated Hospital of Xiamen University"]